Describe the clinical characteristics, treatment approaches, and outcomes of patients with Intracranial germ cell tumors (iGCTs) treated at a single national reference institution in Mexico over a 24-year period, and to assess the variability in treatment regimens and its potential impact on survival and treatment-related toxicity. 

iGCTs are rare central nervous system neoplasms, accounting for approximately 1–3% of all brain tumors. They are classified as germinomas or non-germinomatous germ cell tumors (NGGCTs). These tumors exhibit high sensitivity to chemotherapy and radiotherapy (RT).

There are no standardized guidelines for the treatment of patients with iGCTs.  They requiered multimodal treatment with surgical resections, RT and chemotherapy.  Despite the favorable prognosis of iGCTs, the treatment can lead to significant side effects that can affect the quality of life of the patients. 

It is essential to improve and standardize treatment regimens to minimize variability in chemotherapy cycles and radiotherapy dosing. The implementation of advanced technologies such as intensity-modulated radiotherapy (IMRT) may help reduce radiation-associated side effects and enhance disease-free survival.